Takeda Pharmaceutical must face antitrust litigation over its alleged scheme to delay generic versions of the diabetes drug Actos by exaggerating the scope of its patents to regulators, a federal appeals court in Manhattan ruled Wednesday, August 25.
The US Court of Appeals for the Second Circuit upheld a decision by Judge Ronnie Abrams, who found that Takeda could be liable for effectively tricking the FDA into requiring other drugmakers to challenge Takeda’s patents instead of letting them “carve out” non-infringing methods of use.
Related: Takeda Wants 2nd Circuit To Toss Actos Antitrust Suit
Steven Reed of Morgan, Lewis & Bockius, arguing for Takeda, told the 2nd US Circuit Court of Appeals panel that the Tokyo-based drugmaker had been required by federal law to list two patents that describe combinations of Actos’ active ingredient with other ingredients as pertaining to the drug itself in the Food and Drug Administration’s so-called Orange Book of patents.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI